Faculty ProfilesElizabeth Murphy, MD, PhD
Elizabeth Murphy, MD, DPhil, is Chief of the Endocrinology and Metabolism Division, Director of the Diabetes Center for High Risk Populations and Specialty Lead of the eReferral Program at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California, San Francisco.
As Chief of the Endocrinology and Metabolism Division at SFGH, Dr. Murphy's work has focused on improving access and quality of endocrinology and diabetes care for low income, diverse populations in the San Francisco safety net. As Director of the Diabetes Center for High Risk Populations, she has led the development of novel services such as medical group visits for insulin initiation in English and Spanish, low literacy insulin teaching aids for patients, medication management algorithms for primary care, and targeted outreach to SF County Jail patients. Her team's efforts in health disparities were recognized by the American Diabetes Association's Promising Practice Award of Excellence in 2012 and were an integral part of the Healthy San Francisco Chronic Care Redesign Program recognized by the National Association of Public Hospitals' Safety Net Award in 2010.
Through her work as Specialty Lead of the eReferral program, Dr. Murphy has been instrumental in standardizing the role of the specialist reviewer with an emphasis on improving primary-specialty care communication. In addition she has worked with the Endocrine Society on improving the referral process as part of the ACP High Value Care Coordination Project.
Previously, Dr. Murphy served as the Chief Medical Officer of KineMed, Inc, a biotechnology company focused on the use of stable isotope technology to measure kinetic processes for drug development. There she was responsible for in vivo human studies in diverse areas including insulin resistance and diabetes, lipid metabolism, chronic lymphocytic leukemia, prostate cancer, and bile acid kinetics.
A practicing endocrinologist, Dr. Murphy received the UCSF/San Francisco General Hospital Department of Medicine Subspecialty Consultant of the Year Award in 2011, the John Karum Clinician Educator Award in 2011 for her work with UCSF endocrinology fellows and in 2015 was named a Master Clinician in the Department of Medicine.
Dr. Murphy received her BA in Chemistry from Wellesley College, a D.Phil. in Biochemistry from Oxford University as a Rhodes Scholar, and MD from Harvard Medical School in the Harvard-MIT affiliated Health Sciences and Technology program. She completed her internal medicine residency and endocrinology fellowship training at UCSF.
Recent Articles (10)
Tuvdendorj D, Munoz AO, Ruiz-Barros V, Schwarz JM, Montalto G, Chandalia M, Sowers LC, Rizzo M, Murphy EJ, Abate N. InÂ vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters. Atherosclerosis. 2016 Aug; 251:147-52.
Marshall NE, Murphy EJ, King JC, Haas EK, Lim JY, Wiedrick J, Thornburg KL, Purnell JQ. Comparison of multiple methods to measure maternal fat mass in late gestation. Am J Clin Nutr. 2016 Apr; 103(4):1055-63.
Tuot DS, Leeds K, Murphy EJ, Sarkar U, Lyles CR, Mekonnen T, Chen AH. Facilitators and barriers to implementing electronic referral and/or consultation systems: a qualitative study of 16 health organizations. BMC Health Serv Res. 2015; 15(1):568.
McDermott KA, Rao MR, Nagarathna R, Murphy EJ, Burke A, Nagendra RH, Hecht FM. A yoga intervention for type 2 diabetes risk reduction: a pilot randomized controlled trial. BMC Complement Altern Med. 2014; 14:212.
Saslow LR, Kim S, Daubenmier JJ, Moskowitz JT, Phinney SD, Goldman V, Murphy EJ, Cox RM, Moran P, Hecht FM. A randomized pilot trial of a moderate carbohydrate diet compared to a very low carbohydrate diet in overweight or obese individuals with type 2 diabetes mellitus or prediabetes. PLoS One. 2014; 9(4):e91027.
Tuvdendorj D, Chandalia M, Batbayar T, Saraf M, Beysen C, Murphy EJ, Abate N. Altered subcutaneous abdominal adipose tissue lipid synthesis in obese, insulin-resistant humans. Am J Physiol Endocrinol Metab. 2013 Oct 15; 305(8):E999-E1006.
Okeigwe I, Yeaton-Massey A, Kim S, Vargas JE, Murphy EJ. U-500R and aspart insulin for the treatment of severe insulin resistance in pregnancy associated with pregestational diabetes. J Perinatol. 2013 Mar; 33(3):235-8.